These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12183788)

  • 1. [Local treatment of periarthropathies with the 5-HT3-receptor-antagonist tropisetron].
    Stratz T; Stauber A; Müller W
    Z Orthop Ihre Grenzgeb; 2002; 140(4):394-8. PubMed ID: 12183788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of tendopathies with tropisetron.
    Stratz T; Varga B; Müller W
    Rheumatol Int; 2002 Nov; 22(6):219-21. PubMed ID: 12426658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local treatment of tendinopathies: a comparison between tropisetron and depot corticosteroids combined with local anesthetics.
    Stratz Th; Färber L; Müller W
    Scand J Rheumatol; 2002; 31(6):366-70. PubMed ID: 12492253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
    Müller W; Stratz T
    Scand J Rheumatol Suppl; 2004; 119():44-8. PubMed ID: 15515413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron].
    Stratz T; Müller W
    Schmerz; 2003 Jun; 17(3):200-3. PubMed ID: 12789487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
    Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
    Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia].
    Stratz T; Varga B; Müller W
    Z Rheumatol; 2003 Feb; 62(1):42-5. PubMed ID: 12624803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
    Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
    Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
    Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
    Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
    Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [5-HT3 receptor antagonist als analgetics in rheumatic diseases].
    Müller W; Fiebich BL; Stratz T
    Z Rheumatol; 2006 Oct; 65(6):546, 548-52. PubMed ID: 16450149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone.
    Samborski W; Stratz T; Mackiewicz S; Müller W
    Scand J Rheumatol Suppl; 2004; 119():51-4. PubMed ID: 15515415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the intravenous administration of tropisetron in fibromyalgia patients.
    Müller W; Stratz T
    Scand J Rheumatol Suppl; 2000; 113():59-62. PubMed ID: 11028834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.
    Papadopoulos IA; Georgiou PE; Katsimbri PP; Drosos AA
    Clin Rheumatol; 2000; 19(1):6-8. PubMed ID: 10752491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pilot study with 5-HT3 antagonists. Good outcome in fibromyalgia pain].
    Stratz T; Müller W
    MMW Fortschr Med; 2002 Mar; 144(11):49. PubMed ID: 12066514
    [No Abstract]   [Full Text] [Related]  

  • 17. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.
    Münstedt K; Müller H; Blauth-Eckmeyer E; Stenger K; Zygmunt M; Vahrson H
    Br J Cancer; 1999 Feb; 79(3-4):637-9. PubMed ID: 10027342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [5-HT3 receptor antagonists as a new therapeutic principle in rheumatology?].
    Pongratz D
    Z Rheumatol; 2001 Feb; 60(1):47-8. PubMed ID: 11263014
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
    Stratz T; Müller W
    Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.